A randomized, double-blind, placebo controlled, stage III clinical trial evaluated the efficacy and protection profile of adalimumab like a monotherapy in clients with RA who had failed to answer csDMARDs [191]. The outcome showed both of those statistically sizeable enhancement from the disorder exercise and an excellent basic safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/